Mereo Biopharma Group Plc - ADR
MREO
Market Cap$676.56M
Close$
$2.14
11.5% downside
Current Fair Value
11.5% downsideOvervalued by 11.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $676.56 Million |
|---|---|
| Enterprise Value | $613.96 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.04 |
| Beta | 0.97 |
| Outstanding Shares | 142,354,160 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -18.52 |
|---|---|
| PEG | -14.39 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1700.25 |
| Enterprise Value to EBIT | -16.13 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Mereo Biopharma Group Plc
2,020 employees
CEO: Denise Pollard-Knight Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. The Company has developed a portfolio of six clinical...